Research programme: aggrecanase inhibitors - Amgen

Drug Profile

Research programme: aggrecanase inhibitors - Amgen

Latest Information Update: 30 Mar 2010

Price : $50

At a glance

  • Originator Alantos Pharmaceuticals
  • Class
  • Mechanism of Action Aggrecanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 17 Jul 2007 Alantos has been acquired by Amgen
  • 23 Aug 2006 Early research in Rheumatoid arthritis in USA (unspecified route)
  • 23 Aug 2006 Early research in Osteoarthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top